S 1360

Known as: S-1360, S1360 cpd 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2011
024620022011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
HIV-1 integrase (IN) has become an attractive target since drug resistance against HIV-1 reverse transcriptase (RT) and protease… (More)
Is this relevant?
2009
2009
A three-dimensional model of a complex between HIV-1 integrase (IN), viral DNA, and metal ions that we recently built was used as… (More)
Is this relevant?
2008
2008
Resistance passage studies were conducted with five INIs (integrase inhibitors) that have been tested in clinical trials to date… (More)
Is this relevant?
2008
2008
To gain further insight into the understanding of the antiviral resistance patterns and mechanisms of the integrase strand… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2007
2007
Integrase (IN) is one of the three human immunodeficiency virus type 1 (HIV-1) enzymes essential for effective viral replication… (More)
Is this relevant?
2004
2004
OBJECTIVES Study of HIV-1 resistance development to the diketo analogue S-1360, the first HIV-1 integrase strand transfer… (More)
Is this relevant?
2004
2004
S-1360, a 1,3-diketone derivative, was the first HIV integrase inhibitor to enter human trials. Clinical data suggested… (More)
Is this relevant?
2004
2004
Predicting a bioactive conformation of a ligand is of paramount importance in rational drug design. The task becomes very… (More)
Is this relevant?
Review
2003
Review
2003
Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV… (More)
Is this relevant?
2003
2003
The diketo acid L-708,906 has been reported to be a selective inhibitor of the strand transfer step of the human immunodeficiency… (More)
Is this relevant?